Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Composite photo collage of two players hold chess board game hobby tactic horse queen championship leisure isolated on painted background.

Approvals

Merck steps up as ‘meaningful competitor’ to Gilead with HIV pill approval

The newly approved HIV drug Idvynso will also help Merck diversify as loss of exclusivity looms over its top-selling product, the mega-blockbuster cancer drug Keytruda.

April 22, 2026

1 min read

Tristan Manalac

diffrerent stars on a podium, 3d illustration

IPO

The 5 largest IPOs in biopharma history

With an IPO raise of $625 million, Kailera Therapeutics now holds the new record for the largest public market debut.

April 22, 2026

9 min read

Tristan Manalac

Concept of diabetes control and healthcare. Medical equipment set for measuring sugar level and insulin injections. Insulin pumps, glucometer, phone, insulin, syringe and human hand.

Insights

The next phase of diabetes care

As technology becomes more integrated and personalized, experts say the biggest opportunity in diabetes management is reducing everyday burdens.

April 22, 2026

4 min read

Jennifer C. Smith-Parker

Denali Therapeutic CEO Ryan Watts accepts the Visionary of the Year award at BioHive Live in Salt Lake City, Utah, on April 16, 2026.

C-suite

Denali CEO’s ‘greatest professional moment’ arrives as rare disease drug launches

After receiving the FDA’s greenlight for Hunter syndrome drug Avlayah, Denali Therapeutics CEO Ryan Watts saw the culmination of 20 years of hard work unraveling the mysteries of the blood-brain barrier.

April 22, 2026

7 min read

Annalee Armstrong

Traffic light in green color, with the dusk sky in the background.

Opinion

Why key opinion leader enthusiasm often doesn’t predict future commercial success

While prominent physicians can provide companies with valuable guidance during development, their perspective is limited when it comes to projecting how well or how readily a new product will be adopted. Here’s how to perform rigorous commercial diligence.

April 22, 2026

7 min read

Harris Kaplan

Group Of Employees Being Fired By Their Company.

Layoffs

Replimune cuts will leave over 200 jobless in Massachusetts

Replimune is axing 144 employees at its Woburn headquarters and 80 at its Framingham manufacturing site. The cuts follow the FDA’s second rejection of the biotech’s advanced melanoma candidate.

April 21, 2026

1 min read

Angela Gabriel

Ocean with the wake of the ferry out to Dry Tortugas National Park in Florida Keys

Series A

Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs

With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily oral treatments to patients with central nervous system conditions.

April 21, 2026

1 min read

Gabrielle Masson